Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.59 |
| ▸ | RAB9A | P51151 | 5/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 4/20 | 0.59 |
| ▸ | GAA | P10253 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | DPP4 | P27487 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.47 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8365566 | 0.85 | DPP4 (0.58) | MAPTRAB9AKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL13602607 | 0.84 | KMT2A (0.60) | MAPTRAB9AKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL13649701 | 0.84 | SMN1; SMN2 (0.58) | MAPTRAB9AKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL7026260 | 0.82 | DPP4 (0.56) | MAPTRAB9AKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL13233272 | 0.82 | KMT2A (0.64) | MAPTRAB9AKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL5650522 | 0.82 | SMN1; SMN2 (0.60) | MAPTRAB9AKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL3937141 | 0.80 | MAPT (0.57) | MAPTRAB9AKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL14261145 | 0.80 | MAPT (0.59) | MAPTRAB9AKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL5099213 | 0.79 | SMN1; SMN2 (0.57) | MAPTRAB9AKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL1146057 | 0.79 | SMN1; SMN2 (0.60) | MAPTRAB9AKMT2ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192177-A1 | 2-ARYL pyrrologpyrimidines for A1 and A3 receptors | OSI PHARMACEUTICALS, INC. | 2009-07-30 | — | — | US | disclosed |
| US-20090082369-A1 | Pyrrolo[2,3d]pyrimidine compositions and their use | OSI PHARMACEUTICALS, INC. | 2009-03-26 | — | — | US | disclosed |
| US-7504407-B2 | Compounds specific to adenosine A1 and A3 receptors and uses thereof | OSI PHARMACEUTICALS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080070936-A1 | Compounds specific to adenosine A1 receptors and uses thereof | OSI PHARMACEUTICALS, INC. | 2008-03-20 | — | — | US | disclosed |
| US-20080058383-A1 | Androgen Receptor Modulators | KARO BIO AB (SE) | 2008-03-06 | — | — | US | disclosed |
| US-7288571-B2 | Thyroid receptor ligands and method II | KARO BIO AB (SE) | 2007-10-30 | — | — | US | disclosed |
| US-7160890-B2 | Compounds specific to adenosine A3 receptor and uses thereof | OSI PHARMACEUTICALS, INC. (US) | 2007-01-09 | — | — | US | disclosed |
| US-6680324-B2 | 4-AMINO-6-PHENYL-PYRROLO(2,3-D)PYRIMIDINE DERIVATIVES | OSI PHARMACEUTICALS, INC. | 2004-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192177-A1 | 2-ARYL pyrrologpyrimidines for A1 and A3 receptors | ADORA3, ADORA1, ADORA2A | MAPT 3880/4885RAB9A 2270/4885KMT2A 2686/4885 |
| US-20090082369-A1 | Pyrrolo[2,3d]pyrimidine compositions and their use | ADORA3, ADORA2A, ADORA1 | MAPT 3348/4885RAB9A 1426/4885KMT2A 1854/4885 |
| US-20080070936-A1 | Compounds specific to adenosine A1 receptors and uses thereof | ADORA1, ADORA2A, ADORA3 | MAPT 3985/4885RAB9A 1884/4885KMT2A 2532/4885 |
| US-20080058383-A1 | Androgen Receptor Modulators | NR5A1, ESRRA, AR | MAPT 3258/4885RAB9A 3782/4885KMT2A 3314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.